Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3OTHER_GOV 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 271Carcinoma, Non-Small-Cell Lung 195Prostatic Neoplasms 171Stomach Neoplasms 100Lung Neoplasms 93Squamous Cell Carcinoma of Head and Neck 73Head and Neck Neoplasms 68Esophageal Neoplasms 56Neoplasms 47Neoplasm Metastasis 36Pancreatic Neoplasms 31Nasopharyngeal Carcinoma 30Ovarian Neoplasms 27Sarcoma 26Urinary Bladder Neoplasms 25Triple Negative Breast Neoplasms 20Adenocarcinoma 19Carcinoma, Squamous Cell 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Carcinoma, Ovarian Epithelial 15Unspecified Adult Solid Tumor, Protocol Specific 13Carcinoma, Transitional Cell 13Breast Neoplasms, Male 13Adenocarcinoma of Lung 12Salivary Gland Neoplasms 11Laryngeal Neoplasms 11Small Cell Lung Carcinoma 10Inflammatory Breast Neoplasms 10Uterine Cervical Neoplasms 9

Interventions

pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Carboplatin 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Docetaxel × Clear all
NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Duke University

Phase 2 Terminated
56 enrolled 16 charts
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

307 Hospital of PLA

Phase 3 Completed
104 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡